CHOP will be a provider in Independence Blue Cross’s new Advanced Network for Gene-Based Therapeutics, effective March 1, 2023.

Phase three of the Management of Myelomeningocele Study (MOMS), known as “MOMS3,” is a study monitoring the health outcomes of participants ages15-24.

With support from Jazz Pharmaceuticals, the grant will fund a SU2C Catalyst® Research Team led by Dr. Grohar; the team will investigate new, targeted treatments for patients 10 years and older with Ewing sarcoma.

CHOP researchers have developed a custom-built application to automate determination of engraftment, a key outcome after hematopoietic stem cell transplant.

Check out these learning opportunities from ACOG, NFID, Voices for Vaccines and more, some of which include continuing education credits.

Dr. Sean O’Leary, Chair of AAP’s COID, explains why AAP and CDC recommendations about HPV vaccine differ.

The findings of this recent study underline the importance of accurate public health reporting as we make decisions about vaccines moving forward. Check it out.

Find out about the lingering effects of Epstein-Barr virus, streptococcus, influenza, pneumococcus, Ebola, polio, measles and other infections as well as what to consider in relation to long COVID.

CHOP researchers have developed a new computational tool that can more accurately discover and quantify RNA molecules from these error-prone long-read RNA sequencing data.

Researchers in CHOP’s Pediatric Heart Valve Center have found that the neurotransmitter serotonin can adversely affect the heart’s mitral valve, contributing to a heart disease known as degenerative mitral regurgitation.